TickerFactsScreenerDevelopers

ImmunityBio, Inc. (IBRX) — Cash & Equivalents

Annual figures by fiscal year, from SEC filings.

2012: $116.0K2013: $350.0K2014: $59.10M2015: $175.91M2016: $8.08M2017: $23.87M2018: $16.82M2019: $75.80M2020: $34.91M2021: $181.10M2022: $104.64M2023: $265.45M2024: $143.43M2025: $88.33M$88.33M
2012Cash & Equivalents (USD)2025
Fiscal YearCash & EquivalentsChange YoY
2025$88.33M-38.4%
2024$143.43M-46.0%
2023$265.45M+153.7%
2022$104.64M-42.2%
2021$181.10M+418.7%
2020$34.91M-53.9%
2019$75.80M+350.6%
2018$16.82M-29.5%
2017$23.87M+195.3%
2016$8.08M-95.4%
2015$175.91M+197.6%
2014$59.10M+16786.9%
2013$350.0K+201.7%
2012$116.0K—